Trial Profile
Randomised, Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mcg (2 Actuations of 2.5 Mcg) and 10mcg (2 Actuations of 5mcg)) of BI 1744 CL Inhalation Solution Delivered by the Respimat Inhaler, and One Dose (12mcg) of Foradil Delivered by the Aerolizer Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Olodaterol (Primary) ; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 24 May 2017 Results assessing long-term safety profile of olodaterol from NCT00793624 and NCT00796653 trials presented at the 113th International Conference of the American Thoracic Society
- 11 Sep 2013 Pooled safety analysis results presented at the 23rd Annual Congress of the European Respiratory Society.
- 11 Sep 2013 Results reporting lung function presented at the 23rd Annual Congress of the European Respiratory Society.